Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 24 Feb 2012 Planned end date changed from 1 Dec 2011 to 1 May 2013 as reported by ClinicalTrials.gov.
- 24 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 07 Dec 2009 New trial record